Compare · DCOY vs NVO
DCOY vs NVO
Side-by-side comparison of Decoy Therapeutics Inc. (DCOY) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DCOY and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 64279.0x DCOY ($3.0M).
- Over the past year, DCOY is down 95.3% and NVO is down 45.6% - NVO leads by 49.7 points.
- Both names hit the wire about 8 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 1 for DCOY).
- Company
- Decoy Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $6.11-2.24%
- $42.79+1.42%
- Market cap
- $3.0M
- $191.15B
- 1M return
- +10.29%
- -7.76%
- 1Y return
- -95.34%
- -45.65%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- News (4w)
- 8
- 8
- Recent ratings
- 1
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest DCOY
- Decoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in London
- SEC Form RW filed by Decoy Therapeutics Inc.
- SEC Form DEFA14A filed by Decoy Therapeutics Inc.
- SEC Form DEF 14A filed by Decoy Therapeutics Inc.
- Decoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of Directors
- Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic
- Decoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory Board
- Decoy Therapeutics Inc. filed SEC Form 8-K: Shareholder Director Nominations, Other Events
- SEC Form 10-Q filed by Decoy Therapeutics Inc.
- Amendment: SEC Form 10-K/A filed by Decoy Therapeutics Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care